Company intelligence / Profile preview

Feyenally

Newark, Delaware, United Statesfeyenally.com ↗

Ownership: Private
Development stage: Other

Overview

Feyenally has developed eyeTEST™, a mobile app that enables users to self-examine their eyes for refractive errors using only a smartphone. The technology uses objective testing methods—analyzing photos of the patient’s eyes with AI/neural networks—to provide accurate and repeatable results comparable to traditional optometrist visits. Initial real-world tests showed measurement accuracy within ±0.45 diopters for spherical and cylindrical errors and 30° for axis error. MDR & FDA certifications are in progress.

Therapeutic areas: Ophthalmology
Modalities: DeviceMobile appArtificial intelligence-based diagnostic tool
Industry: Digital Health Medical Devices

Beyond the preview

Go deeper on Feyenally.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Feyenally.

Explore the full profile